Form 4: Director Tamara Fountain Receives Sight Sciences RSU Grant

Sentiment:

Statement of Changes in Beneficial Ownership


Director Tamara Fountain was granted 28,261 restricted stock units as part of the Sight Sciences, Inc. non-employee director compensation program.

Summary

  • Director Tamara Fountain received a grant of 28,261 restricted stock units (RSUs) on June 4, 2026.
  • The grant is valued at approximately $130,000 based on the closing price on the grant date.
  • The RSUs are subject to a one-year vesting period, vesting on the earlier of June 4, 2027, or the date of the 2027 annual meeting of stockholders.
  • Following this transaction, the director's total beneficial ownership is 109,650 shares, including the unvested RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

  • Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

  • None identified; this is a standard equity compensation disclosure.

Risks

  • Vesting is contingent upon the director's continued service on the board through the vesting date.

Future Outlook

The RSUs will vest on June 4, 2027, or the date of the 2027 annual meeting, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the medical device industry to ensure board members maintain a vested interest in company performance.

Comparison to Industry Standards

  • The grant structure aligns with standard equity compensation practices for mid-cap medical technology companies.
  • The use of RSUs as a primary vehicle for director compensation is consistent with peer companies in the ophthalmic device sector.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Director CompensationGrant of RSUs under the Non-Employee Director Compensation Program.06/04/2026Standard alignment of director incentives with shareholder interests.

Stakeholder Impact

  • Minimal impact on shareholders as this is a standard compensation event.

Next Steps

  • Vesting of the 28,261 RSUs on June 4, 2027, or the 2027 annual meeting date.

Key Dates

DateDescription
06/04/2026Date of RSU grant and earliest transaction.
06/05/2026Date of filing.
06/04/2027Vesting date for the granted RSUs.

Keywords

Sight Sciences, SGHT, Form 4, Insider Transaction, Director Compensation, Restricted Stock Units

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.